TG Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $799.5M+143.0% YoYTTM through 30 Jun 2026
Net Income $441.5M+1,788.1% YoYTTM through 30 Jun 2026
Free Cash Flow $17.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | 17.1% |
| Operating Margin | 17.1% |
| Net Margin | 55.2% |
Returns
73.1%ROE
26.9%ROA
50.9%ROIC
Balance Sheet Health
Debt / Equity1.23x
Current Ratio4.27x
Net Debt$262.8M
Cash & Equivalents$482.6M
Quality Metrics
Altman Z-Score5.66
Piotroski F-Score6 / 9
FCF Margin2.2%
Rule of 4022.3
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $616.3M
Diluted EPS$2.74TTMFY2025: $2.77
Dividend
No dividend
Capital Allocation
R&D Spend$225.8M
Capex Intensity0.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| BRIUMVI U.S. Product Sales | $594.1M | ||
| Ex-U.S. Product Sales (Neuraxpharm) | $12.8M |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.